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Agents that target topoisomerase I are widely utilized
to treat human cancer. Previous studies have indicated
that both the ataxia telangiectasia mutated (ATM)/
checkpoint kinase (Chk) 2 and ATM- and Rad 3-related
(ATR)/Chk1 checkpoint pathways are activated after
treatment with these agents. The relative contributions
of these two pathways to survival of cells after treatment with topoisomerase I poisons are currently unknown. To address this issue, we assessed the roles of
ATR, Chk1, ATM, and Chk2 in cells treated with the
topoisomerase I poisons camptothecin and 7-ethyl-10hydroxycamptothecin (SN-38), the active metabolite of
irinotecan. Colony forming assays demonstrated that
down-regulation of ATR or Chk1 sensitized cells to
SN-38 and camptothecin. In contrast, ATM and Chk2 had
minimal effect of sensitivity to SN-38 or camptothecin.
Additional experiments demonstrated that the Hsp90
inhibitor 17-allylamino-17-demethoxygeldanamycin,
which down-regulates Chk1, also sensitized a variety of
human carcinoma cell lines to SN-38. Collectively, these
results show that the ATR/Chk1 pathway plays a predominant role in the response to topoisomerase I inhibitors in carcinoma cells and identify a potential approach for enhancing the efficacy of these drugs.

In response to different types of DNA damage, a number of
cell cycle checkpoint pathways are activated. These pathways
typically involve detection of damage by one or more DNA
damage sensors followed by activation of a series of kinases
that regulate cellular responses, including cell cycle arrest and
DNA repair (reviewed in Refs. 1 and 2).
One of these pathways involves the sequential action of the
kinases ATM1 and Chk2. According to current understanding,
DNA double-strand breaks and other changes in chromatin
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structure lead to autophosphorylation of the ATM homodimer
(3), which activates ATM and facilitates phosphorylation of a
number of substrates (2, 4), including Chk2. Once activated by
phosphorylation on Thr68 (5), Chk2 then phosphorylates p53,
contributing to stabilization of this transcription factor and
subsequent expression of the cyclin-dependent kinase inhibitor
p21 (1, 2, 6). Chk2 also phosphorylates members of the Cdc25
family, contributing to inhibition (Cdc25C) or degradation
(Cdc25A) of these phosphatases and preventing them from
activating cyclin-dependent kinase complexes that drive cell
cycle progression.
A second but related cell cycle checkpoint pathway involves
sequential action of the kinases ATR and Chk1. When replication forks stall, regions of single-stranded DNA are produced
by continued helicase action (7). The exposed single-stranded
DNA is bound by replication protein A (7–10), which facilitates
the binding of the ATR-ATRIP complex to chromatin (9, 10). At
the same time, the preassembled clamp-like Rad9-Hus1-Rad1
complex (the 9-1-1 complex) (11–13) is loaded onto the chromatin by a clamp loader consisting of Rad17 and the four replication factor C small subunits (14, 15). The chromatin-bound
9-1-1 complex facilitates ATR-mediated phosphorylation and
activation of Chk1 (reviewed in Ref. 16). Chk1 in turn phosphorylates (17–20) and causes proteolytic destruction of the
phosphatase Cdc25A (21), which activates cyclin-dependent
kinase 2-cyclin E and cyclin-dependent kinase 2-cyclin A, two
complexes that drive S-phase progression replication fork firing (reviewed in Ref. 22). In addition, Chk1 helps stabilize
stalled replication forks (23, 24), providing additional protection from replication stress.
Previous studies have suggested that the ATM/Chk2 pathway modulates the response of cells to camptothecin and camptothecin derivatives. These agents, which are widely used in
the treatment of human cancers (25), inhibit the religation step
of topoisomerase I (26), thereby stabilizing covalent topoisomerase I-DNA complexes (27, 28). After treatment with high
(micromolar) camptothecin concentrations, DNA double-strand
breaks occur in the vicinity of advancing replication forks (29 –
31). Additional studies have shown that concurrent treatment
with a replication inhibitor such as aphidicolin diminishes the
number of replication-associated breaks (31) and the cytotoxicity of camptothecin (30, 32). Collectively, these observations
have led to a model in which the cytotoxicity of camptothecin is
attributed to DNA double-strand breaks that result from collisions between advancing replication forks and drug-stabilized
topoisomerase I-DNA complexes (33). Consistent with this
model, ATM-deficient cells, which exhibit diminished ability to
respond to DNA double-strand breaks, have been reported to
exhibit camptothecin hypersensitivity (34 –37).
More recent studies implicated the ATR/Chk1 pathway in
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the response of cells to camptothecin analogs. Shao et al. (38)
reported that UCN-01, an inhibitor of Chk1 (39 – 41), diminishes the S-phase arrest observed after camptothecin. Subsequent studies detected 9-1-1 clamp loading (42, 43) and Chk1
activation (43, 44) after treatment of log-phase cells with camptothecin or camptothecin derivatives. Additional experiments
demonstrated that interruption of the ATR/Chk1 pathway by
expression of a dominant negative ATR allele (44) or targeted
disruption of the Rad9 (43) or Hus1 genes (45) reduces the
survival of mammalian cells exposed to the nanomolar concentrations of camptothecin derivatives that are encountered in
the clinical setting (25, 46). Parallel studies in yeast have
suggested that deletion of genes encoding 9-1-1 complex subunits, the 9-1-1 clamp loader, or the ATR homolog Mec1 also
sensitizes cells to topoisomerase I poisoning (47).
The preceding studies have implicated the ATM/Chk2 and
ATR/Chk1 pathways in the response to topoisomerase I poisons
but have not identified their relative contributions. To address
this issue, the present study utilized siRNA, gene-deleted cells,
and pharmacological manipulations to reexamine the relative
roles of the ATM/Chk2 and ATR/Chk1 pathways in protecting
cells from camptothecin derivatives. Results of this study not
only demonstrate a more prominent role for the ATR/Chk1
pathway but also identify a potential strategy for enhancing
the cytotoxicity of topoisomerase I poisons.
EXPERIMENTAL PROCEDURES

Materials—17-AAG was obtained from the Developmental Therapeutics Program, National Cancer Institute (Bethesda, MD). SN-38 was
a kind gift from L. P. McGovern (Pharmacia Upjohn, Kalamazoo, MI).
Reagents were purchased from the following suppliers: Opti-MEM medium and Lipofectamine 2000, Invitrogen; and camptothecin, Sigma.
Antibodies to the following antigens were purchased from the indicated
manufacturers: Akt, PDK1, phospho-Ser345-Chk1, and phospho-Ser21/9
glycogen synthase kinase-3␣/␤, Cell Signaling Technology (Beverly,
MA); total glycogen synthase kinase-3␤ and ATR, Oncogene Research
(San Diego, CA); and ATM, ␤-actin, and Chk1, Santa Cruz Biotechnology (Santa Cruz, CA). Murine antibodies against Chk2, Hsp90, and
topoisomerase I were kind gifts from Junjie Chen, David Toft (both at
Mayo Clinic, Rochester, MN), and Y.-C. Cheng (Yale University, New
Haven, CT), respectively.
Cell Culture—HeLa human cervical cancer cells were cultured in
RPMI 1640 medium containing 10% fetal bovine serum and 2 mM
glutamine (medium A). HCT 116 human colon cancer cells and their
Chk2⫺/⫺ derivative (48) were kindly provided by B. Vogelstein (Johns
Hopkins University, Baltimore, MD) and grown in medium A supplemented with 100 units/ml penicillin G and 100 g/ml streptomycin
(medium B). T98G cells were grown in medium B supplemented with 1
mM sodium pyruvate. HCT 116 cells from American Type Culture
Collection (Manassas, VA) were propagated in McCoy’s 5A medium
containing 10% fetal bovine serum, 100 units/ml penicillin G, 100 g/ml
streptomycin, and 2 mM glutamine. Identical results were obtained for
the experiment in Fig. 5 using either HCT 116 cell isolate.
siRNA Transfections—On day 1, HeLa or U2OS cells (1 ⫻ 106) were
plated in 35-mm tissue culture dishes and incubated overnight. On day
2, after cells were washed twice with Opti-MEM medium, 2 ml of
Opti-MEM were added to each plate. Four hundred nmol of control
siRNA 1 (Dharmacon, Lafayette, CO), ATR siRNA (49), Chk1 siRNA
(18), PDK1 siRNA (50), or ATM siRNA (51) were complexed with 10 l
of Lipofectamine 2000 in 0.5 ml of Opti-MEM for 20 min. Following
addition of the lipid-siRNA complexes to the cells, the cultures were
incubated for 7–9 h before addition of 1 ml of Opti-MEM containing 30%
fetal bovine serum. The transfections were repeated on day 3. On day 4,
the cultures were trypsinized and replated in 100-mm tissue culture
dishes containing medium B. On day 5, cells were harvested for immunoblotting or exposed to drugs as described below.
Clonogenic Assays—HeLa and U2OS cell clonogenic assays were
performed on the siRNA-transfected cells 48 h after the second transfection. The cells were trypsinized, plated at 300 cells/plate in replicate
60-mm dishes containing medium A, allowed to adhere for 4 h, and
treated with the indicated concentrations of SN-38 or camptothecin for
24 h. Following drug treatment, cells were washed with RPMI 1640
medium, cultured for 7 days in medium A, and stained with Coomassie
Brilliant Blue. Colonies containing ⱖ50 cells were counted.

FIG. 1. Effect of SN-38 on phosphorylation of Chk1 and Chk2.
A, dose-response curve. Log-phase HeLa cells were treated for 6 h with
diluent (0.1% Me2SO, lane 1) or SN-38 at 12.5, 25, 50, 100, or 200 nM
(lanes 2– 6, respectively). At the end of the incubation, whole cell lysates
were prepared, subjected to SDS-PAGE, transferred to nitrocellulose,
and probed with reagents that recognize phospho-Ser345-Chk1, phospho-Thr68-Chk2, total Chk1, total Chk2, or, as a control, ␤-actin. B, time
course. Log-phase HeLa cells were treated with 100 nM SN-38 for the
indicated length of time. At the completion of the incubation, whole cell
lysates were analyzed as indicated in A.
Colony forming assays were performed in untransfected HeLa cells
and the other cell lines with the following modifications: 1) transfection
was omitted; 2) cells were plated at 250 (T98G), 300 (HeLa), or 500
(HCT 116) cells/plate in 60-mm (HeLa) or 35-mm dishes (T98G and
HCT 116) in their respective media and allowed to adhere for 14 –16 h;
and 3) after the 24-h drug exposure, cells were cultured for 7– 8 (HeLa,
HCT 116) or 9 –10 days (T98G) to allow colonies to form.
Immunoblotting—After treatment with drug or diluent as indicated in
the figure legends, cells were washed three times with ice-cold RPMI 1640
medium containing 10 mM HEPES (pH 7.4 at 4 °C) and solubilized by
addition of 6 M guanidine hydrochloride containing 250 mM Tris-HCl (pH
8.5 at 20 °C), 10 mM EDTA, 1% (v/v) 2-mercaptoethanol, and 1 mM freshly
added phenylmethylsulfonyl fluoride directly to the plates. After preparation for electrophoresis as described previously (52), aliquots containing
50 g of protein (determined by the bicinchoninic acid method) (53) were
separated on SDS-polyacrylamide gels containing 5–15% (w/v) acrylamide
gradients, electrophoretically transferred to nitrocellulose, and probed
with immunological reagents as described previously (54). Alternatively,
cell lysates were prepared from siRNA-transfected cells and probed by
immunoblotting as described previously (55).
Statistical Analysis—Clonogenic experiments in tissue culture cell
lines were performed a minimum of three times. The method of Chou and
Talalay (56) was employed as described previously (57–59) to determine
whether the effects of the SN-38/17-AAG combination were synergistic.
RESULTS

A Predominant Role for the ATR/Chk1 Pathways in Camptothecin Sensitivity—Previous studies demonstrated that Chk1
and Chk2 are both activated after treatment with the topoisomerase I poisons topotecan (44) or camptothecin (43). Consistent with these results, treatment of HeLa cells with the
camptothecin derivative SN-38, the active metabolite of the
widely used chemotherapeutic agent irinotecan (25, 46), resulted in the concentration- and time-dependent phosphorylation of Chk1 on Ser345 and Chk2 on Thr68, sites that are
required for activation of the kinases (Fig. 1). Chk1 phosphorylation was detected after treatment for 6 h with SN-38 at
concentrations as low as 12.5 nM (Fig. 1A) and was present
within 1 h after treatment with 100 nM SN-38 (Fig. 1B). Likewise, phosphorylation of Chk2 was evident after treatment
with 12.5 nM SN-38 (Fig. 1A) for 6 h or after treatment with 100
nM SN-38 for 1 h (Fig. 1B).
To assess the potential importance of activating the ATR/
Chk1 pathway, HeLa cells were transfected with an siRNA
duplex oligonucleotide that down-regulates ATR (Fig. 2A, inset), treated for 24 h with increasing concentrations of SN-38,
washed, and incubated for 7 days so that surviving cells could
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FIG. 2. Drug sensitivity after transfection with siRNA that down-regulates ATR or Chk1. HeLa cells (A⫺E) or U2OS cells (F) were
transfected twice with siRNA as described under “Experimental Procedures.” Two days after the second transfection, cells were exposed to diluent
(0.1% Me2SO) and the indicated concentrations of SN-38 (A, B, D, and F), or camptothecin (C) for 24 h. At the completion of the drug treatment,
cells were washed and incubated in drug-free medium for 7 days to allow colonies to form. Alternatively, cells in E were subjected to the indicated
dose of radiation from a 137Cs source and incubated in drug-free medium for 8 days to allow colonies to form. Error bars, ⫾S.D. from triplicate
samples. Insets in A, B, D, and F, whole cell lysates were prepared from additional transfected cells at the time of drug treatment. Aliquots
containing 50 g of protein were subjected to SDS-PAGE and probed for the indicated polypeptides. ␤-Actin or Hsp90 served as a loading control.

form colonies. Results of this analysis (Fig. 2A) demonstrated
that ATR down-regulation increased SN-38 sensitivity, with a
3-fold decrease in the IC50. Likewise, siRNA-mediated downregulation of Chk1 (Fig. 2B, inset) was accompanied by a 2-fold
decrease in the SN-38 IC50 (Fig. 2B). Similar results were
observed with the parent drug, camptothecin (Fig. 2C). These
results are consistent with previous studies showing a comparable effect after disruption of ATR signaling by conditional
expression of a dominant negative ATR construct (44) or by
Rad9 deletion (43). siRNA to PDK1, a polypeptide that is
discussed in greater detail below, diminished the levels of
PDK1 as well as phosphorylation of the PDK1 substrate (Fig.
2D, inset) Akt on Thr308, a site phosphorylated by PDK1 and
required for Akt activation. However, PDK1 siRNA did not
sensitize HeLa cells to SN-38 but instead slightly decreased the
antiproliferative effects of this agent (Fig. 2D).
Several additional observations argue against the possibility
that the sensitizing effects of siRNA targeting ATR or Chk1 are
due to nonspecific toxicity. First, the cloning efficiencies of
HeLa cells transfected with ATR siRNA and Chk1 siRNA were
87 ⫾ 10% (mean ⫾ S.D., n ⫽ 4) and 74 ⫾ 19% (n ⫽ 9),
respectively, of cells treated with control siRNA, ruling out the
possibility that the siRNA was killing the bulk of the cells and
allowing outgrowth of a nonrepresentative population. Second,
whereas Chk1 siRNA sensitized cells to camptothecins (Fig.
2C) as well as antimetabolites such as cytarabine,2 it had no
effect on sensitivity to ionizing radiation (Fig. 2E), consistent
with predominant involvement of the ATM pathway in the
response to DNA double-strand breaks.
To rule out the possibility that the results obtained were
unique to HeLa cells, U2OS human osteosarcoma cells were
transfected with ATR siRNA. Once again, the cells were sen2

L. M. Karnitz and K. Flatten, unpublished observations.

sitized to SN-38 (Fig. 2F). Because U2OS cells contain an intact
p53 tumor suppressor protein (60), these results also rule out
the possibility that ATR siRNA-induced sensitization to camptothecins occurs only in cells with an inactive p53 pathway.
In contrast to ATR or Chk1 down-regulation, down-regulation
of components of the ATM/Chk2 pathway had a much smaller
effect on SN-38 sensitivity. Transfection of HeLa cells with ATM
siRNA depleted ATM (Fig. 3A, inset) but had minimal effect on
SN-38 sensitivity (Fig. 3A). In view of this surprising result,
similar experiments were performed using the parent drug,
camptothecin. Once again little sensitization was observed (Fig.
3B). Importantly, the same siRNA transfectants were sensitized
to ionizing radiation (Fig. 3C). To further examine the effect of
interrupting the ATM/Chk2 pathway, SN-38 sensitivity was
compared in parental HCT 116 colon cancer cells and their
Chk2⫺/⫺ derivative. Once again, little difference in SN-38 (Fig.
3D) or camptothecin (Fig. 3E) sensitivity was observed. When
combined with the results in Fig. 2, these observations suggest
that the ATR/Chk1 pathway plays a predominant role in protecting cells from topoisomerase I poisons.
Synergistic Effects of SN-38 and Hsp90 Inhibitors—In view
of these results, we predicted that Chk1 depletion by other
means would also sensitize cells to the antiproliferative effects
of SN-38. Recent results demonstrated that Chk1 is a client of
the Hsp90 chaperone complex and, correspondingly, showed
that treatment with the Hsp90 inhibitor 17-AAG resulted in
selective down-regulation of Chk1 without changes in other
known components of the ATR/Chk1 and ATM/Chk2 pathways
(55). Examination in HeLa cells demonstrated that Chk1 downregulation is evident at 125 nM 17-AAG (Fig. 4A), a concentration that is readily sustained for ⬎24 h in the clinical setting
(61). Like Chk1, other Hsp90 client proteins such as PDK1 and
Akt1 were depleted, whereas no change in topoisomerase I
levels was observed (Fig. 4A).
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FIG. 3. Effect of ATM siRNA or Chk2 gene deletion. A and B, 2 days after the second transfection with ATM siRNA, cells were exposed for
24 h to the indicated concentrations of SN-38 or camptothecin. At the completion of the drug treatment, cells were washed with drug-free medium
and allowed to form colonies. Inset in A, whole cell lysates were prepared from additional transfected cells and analyzed for ATM levels by
immunoblotting. C, 2 days after the second transfection with ATM siRNA, cells were subjected to the indicated dose of radiation from a 137Cs source
and incubated in drug-free medium for 8 days to allow colonies to form. D and E, parental or Chk2⫺/⫺ HCT 116 cells were treated for 24 h with
the indicated concentration of SN-38 or camptothecin and then washed and incubated in drug-free medium until colonies formed. Inset in D, whole
cell lysates from the same cultures of parental and Chk2⫺/⫺ cells were subjected to SDS-PAGE and immunoblotting. Hsp90 served as a loading
control. Error bars, ⫾S.D. from triplicate samples.

FIG. 4. Synergistic effect of SN-38 and the Hsp90 inhibitor 17-AAG in HeLa cells. A, log-phase HeLa cells were treated for 24 h with
diluent (0.1% Me2SO, lane 1) or 17-AAG at 62.5, 125, 250, 500, and 1000 nM (lanes 2– 6, respectively). At the end of the drug treatment, whole cell
lysates were prepared as described under “Experimental Procedures.” Aliquots containing 50 g of protein were subjected to SDS-PAGE and
probed with reagents that recognize the indicated antigens. ␤-Actin served as a loading control. B and C, HeLa cells were treated for 24 h with the
indicated concentrations of SN-38 alone (B), 17-AAG alone (C), or a 1:6 ratio of SN-38 to 17-AAG (B and C). The final Me2SO concentration was
0.2% in all cultures. At the completion of the incubation, cells were washed and incubated in drug-free medium until colonies formed. Error bars,
⫾S.D. from triplicate samples. D, combination index plot derived from the data in B and C. Data were analyzed by the method of Chou and Talalay
(56), according to the assumption that effects of the two agents are mutually exclusive. A combination index of ⬍1.0 indicates synergy. Results of
this analysis are equivalent to isobologram analysis (62). Results calculated under the assumption that effects of the agents are mutually
nonexclusive are also indicated.
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FIG. 5. Effects of the 17-AAG/SN-38 combination in HCT 116 colon cancer and T98G glioblastoma cells. A and D, HCT 116 (A) or T98G
(D) cells were treated for 24 h with diluent (0.1% Me2SO, lane 1) or 17-AAG at 62.5, 125, 250, 500, or 1000 nM (lanes 2– 6, respectively). After drug
treatment, whole cell lysates were prepared. Aliquots containing 50 g of protein were subjected to SDS-PAGE followed by immunoblotting with
reagents that recognize the indicated antigens. ␤-Actin served as a loading control. B and E, HCT 116 (B) or T98G (E) cells were treated for 24 h
with SN-38 alone or the SN-38/17-AAG combination at a fixed ratio of 1:8 (B) or 1:2 (E). At the end of the incubation, cells were washed and
incubated in drug-free medium until colonies formed. Error bars, ⫾S.D. from triplicate aliquots. C and F, combination index plots. Data from the
experiments shown in B and E, along with simultaneously derived results obtained after treatment with 17-AAG alone (see Fig. 4C), were analyzed
by the method of Chou and Talalay (56). A combination index of ⬍1.0 indicates synergy.

To assess whether loss of Hsp90 clients was accompanied by
enhanced SN-38 sensitivity, cells were treated for 24 h with
increasing concentrations of SN-38, 17-AAG, or a combination
of both agents. To facilitate subsequent analysis, the combination consisted of the two agents at a fixed ratio determined by
their respective IC50 values, and the fixed ratio was applied at
a number of concentrations that included one-half, fiveeighths, three-fourths, seven-eighths, and 1.5 times the individual IC50 values. This approach has been widely applied in
previous analyses of new drug combinations (56 –59). Results of
this analysis showed that the combination demonstrated
greater antiproliferative effects than either agent alone (Fig. 4,
B and C). Formal analysis by the method of Chou and Talalay
(56) was performed under the assumption that effects of the
two agents are mutually exclusive, an assumption that renders
this approach equivalent to the isobologram method (62). This
analysis (Fig. 4D) demonstrated that effects of the two agents
were synergistic, as evidenced by a combination index of ⬍1
over a wide range of concentrations (56). In repeated experiments, the combination index was 0.75 ⫾ 0.09 (mean ⫾ S.D.,
n ⫽ 3) at the IC90.
To rule out the possibility that this synergy was unique to
the HeLa cell line, HCT116 colon cancer cells and T98G human
glioblastoma cells were subjected to similar analyses. Immunoblotting demonstrated that 17-AAG induced down-regulation of Chk1 in these cell lines at even lower concentrations
(Fig. 5, A and D), with no effect on topoisomerase I levels (data
not shown). Once again, the antiproliferative effects of the
SN-38/17-AAG combination were greater than those of either
agent alone (Fig. 5, B and E; data not shown). Analysis by the
method of Chou and Talalay (56) indicated synergy in both cell
lines (Fig. 5, C and F), with combination indices of 0.63 ⫾ 0.12
(n ⫽ 8) and 0.65 ⫾ .10 (n ⫽ 3), respectively, at the IC90 values.

DISCUSSION

Results of the present study demonstrated that Chk1 downregulation enhances sensitivity to the topoisomerase I poison
SN-38, whereas down-regulation of ATM or deletion of Chk2
has a much smaller effect. Additional experiments showed that
17-AAG, which down-regulates Chk1, and SN-38 synergize in
killing cells. These results have potentially important implications for the mechanism of action of topoisomerase I poisons
and future clinical development of these agents.
Early studies indicated that fibroblasts and lymphoblastoid
lines from ataxia telangiectasia patients are hypersensitive to
camptothecin (34 –37). These studies suggested an important role
for the ATM/Chk2 pathway in response to topoisomerase I poisons and provided support for a model in which the cytotoxicity of
topoisomerase I poisons results from the formation of DNA double-strand breaks as a consequence of a collision between advancing replication forks and drug-stabilized topoisomerase I-DNA
covalent complexes. More recent studies found that disruption of
the ATR/Chk1 pathway also sensitizes cells to topoisomerase I
poisons (43, 44, 63). Because this pathway is robustly activated
by agents that stall advancing replication forks (64), activation of
this pathway by topoisomerase I poisons was initially somewhat
surprising. The present results using siRNA constructs not only
confirm that down-regulation of ATR or Chk1 sensitizes cells to
topoisomerase I poisons, but they also suggest that the ATR/
Chk1 pathway plays a more prominent role than the ATM/Chk2
pathway in the response to these agents.
These results appear to be at odds with earlier reports suggesting that ATM inactivation enhances camptothecin sensitivity. Several differences between these studies might contribute to the disparate conclusions. First, the results may be due
to cell line differences. The earlier studies utilized fibroblast
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and lymphoblastoid cell lines, whereas the present study employed epithelium-derived cancer cell lines. Second, the earlier
studies compared cell lines from different individuals, raising
the possibility that factors other than ATM status affected the
results. In contrast, the present study used a single cell line
treated with siRNA and an isogenic pair of cell lines differing in
targeted deletion of Chk2 to reduce the number of uncontrolled
variables. Third, the siRNA-mediated depletion of ATM was
incomplete and, therefore, might have been less effective than
the ATM inactivation seen in ataxia telangiectasia cells. It is
important to point out, however, that this ATM down-regulation was sufficient to sensitize the cells to ionizing radiation
(Fig. 3C). Moreover, deletion of Chk2 did not markedly alter
SN-38 or camptothecin sensitivity (Fig. 3, D and E). Collectively, our results in two model systems suggest that downregulation of the ATM/Chk2 pathway has a limited effect on
sensitivity to topoisomerase I poisons.
Additional experiments in a wider range of model systems
might be warranted to further confirm the conclusion that the
ATR/Chk1 signaling pathway plays a predominant role in response to topoisomerase I poisons. Nonetheless, the present
observations suggest the interesting possibility that stalling of
advancing replication forks, rather than generation of doublestrand breaks, is important in the antiproliferative effect of
topoisomerase I poisons at the nanomolar drug concentrations
that are achieved in the clinical setting (25, 46).
The present results also demonstrated that the antiproliferative effects of SN-38 are enhanced in a synergistic fashion
by simultaneous administration of the Hsp90 inhibitor 17AAG. These effects were observed in HeLa cells (Fig. 4D),
which have a nonfunctional p53 pathway as a consequence of
papilloma virus E6 protein expression (65), as well as HCT 116
cells, which have an intact p53 pathway (66) (Fig. 5C). These
synergistic effects were observed at 17-AAG concentrations in
the 50 –300 nM range. Recent studies have demonstrated that
concentrations of 17-AAG and its active metabolite 17-aminogeldanamycin exceed 300 nM for 16 and 24 h, respectively,
after drug administration in the clinical setting (61). At these
concentrations, Chk1 down-regulation is observed in a variety
of cell lines (55) (Figs. 4A and 5, A and D). These observations
provide a rationale for further preclinical and possible clinical
studies of this combination.
Because 17-AAG induces the down-regulation of a variety of
Hsp90 clients in addition to Chk1 (67, 68), it is possible that
effects on other Hsp90 client proteins contribute to the observed synergy. Previous studies from other laboratories suggested that down-regulation of PDK1 (69) and Akt (70, 71)
might contribute to the antiproliferative effects of 17-AAG
alone or in drug combinations. In the present study, PDK1
siRNA blocked the activating phosphorylation of Akt (Fig. 2D,
inset) but did not sensitize cells to SN-38 (Fig. 2D), most likely
because inhibition of the phosphatidylinositol-3 kinase/PDK1/
Akt pathway inhibits the S-phase progression required for the
cytotoxic effects of topoisomerase I poisons. These observations
suggest that Hsp90 clients contribute differentially to the sensitization observed in Figs. 4 and 5 and further highlight the
potential importance of Chk1 down-regulation. Although the
results shown in Fig. 2 strongly suggest that Chk1 depletion
contributes to the effectiveness of the SN-38/17-AAG combination, additional studies are required to assess the potential role
of other Hsp90 clients in this synergy.
In summary, the present results highlight the importance of
the ATR/Chk1 pathway in survival of cancer cells after treatment with topoisomerase I poisons. In addition, these studies
demonstrate that Chk1 down-regulation by siRNA or 17-AAG
can sensitize cancer cells to camptothecin derivatives. These

observations raise the possibility that inhibition of the ATR/
Chk1 pathway might enhance the therapeutic effects of topoisomerase I poisons.
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